Blog
-
Acasti Pharmaceuticals – market begins to wake up to the explosive upside on offer should CaPre Phase 3 trials prove successful
By Richard Jennings It has been a slow burn for followers of us into Nasdaq listed Acasti Pharmaceuticals (ACST) as per our original article per HERE but we believe that the stock is now primed to move decisively ahead as the company moves up the most important stage of the pharma sector“value proving” curve – […]